GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses  patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade(TM) is currently in the pivotal Phase III PACT study in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, RSV, seasonal and pandemic flu, and foot and mouth disease.

Corporate Counsel
Hogan & Hartson LLP
Baltimore, MD

Independent Accountants
KPMG LLP
Washington, D.C.

Investor Relations Contact
Danielle M. DiPirro
Corporate Communications Specialist
65 West Watkins Mill Road
Gaithersburg, MD 20878
301-944-1877
Email Investor Relations here

Media Contact
Gregory Q. Tiberend
Tiberend Strategic Advisors, Inc.
35 W. 35th Street, 5th Floor
New York, NY 10001
212-827-0020
Email Media Relations here